Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...

March 10 (Reuters) - Eli Lilly (LLY.N), opens new tab ... In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025.

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

In that time, Eli Lilly has seen explosive growth, largely due to its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound. Mounjaro brought in $11.5 billion in sales in 2024 ...

Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket. The company also launched new 7.5-mg and 10-mg single-use vials, which cost $ ...

Like many pharma stocks, Eli Lilly (NYSE ... about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes.